Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Benjamin Farahnik, Kourosh Beroukhim, Michael Abrouk, et al.
Dermatology and Therapy (2016) Vol. 6, Iss. 2, pp. 111-124
Open Access | Times Cited: 134

Showing 26-50 of 134 citing articles:

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
Ke He, Kaidi Zhao, Tingyi Yin, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, et al.
Journal of Crohn s and Colitis (2017) Vol. 12, Iss. 1, pp. 105-119
Closed Access | Times Cited: 83
Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation
Manish K. Jha, Madhukar H. Trivedi
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 1, pp. 233-233
Open Access | Times Cited: 72
Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis
Jeffrey Crowley, Richard B. Warren, Jennifer Cather
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 33, Iss. 9, pp. 1676-1684
Open Access | Times Cited: 72
Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders
Anna Balato, Emanuele Scala, Nicola Balato, et al.
Expert Opinion on Biological Therapy (2017), pp. 1-12
Closed Access | Times Cited: 67
Anti‐IL‐23 and Anti‐IL‐17 Biologic Agents for the Treatment of Immune‐Mediated Inflammatory Conditions
Jillian Frieder, Darío Kivelevitch, Isabel Haugh, et al.
Clinical Pharmacology & Therapeutics (2017) Vol. 103, Iss. 1, pp. 88-101
Closed Access | Times Cited: 65
Clinical and Genetic Heterogeneity of CARD14 Mutations in Psoriatic Skin Disease
Laura Israël, Mark Mellett
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 65
Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis
Kathryn L. Pepple, Phoebe Lin
Ophthalmology (2018) Vol. 125, Iss. 12, pp. 1977-1983
Open Access | Times Cited: 62
Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)
Theresa Benezeder, Peter Wolf
Seminars in Immunopathology (2019) Vol. 41, Iss. 6, pp. 633-644
Open Access | Times Cited: 61
Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center
Yi‐Wei Huang, Tsen‐Fang Tsai
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 43
Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study*
Ruth Oliver, James G. Krueger, Sophie Glatt, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 4, pp. 652-663
Open Access | Times Cited: 41
Effects of Natural Polyphenols on Skin and Hair Health: A Review
Mang Sun, Ya Deng, Xining Cao, et al.
Molecules (2022) Vol. 27, Iss. 22, pp. 7832-7832
Open Access | Times Cited: 37
Annoying Psoriasis and Atopic Dermatitis: A Narrative Review
Wei‐Yu Chen, Shao-Chuan Chen, Shou-Yi Hsu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4898-4898
Open Access | Times Cited: 36
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease
Alfonso Motolese, Manuela Ceccarelli, Laura Macca, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 228-228
Open Access | Times Cited: 29
Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors
George Martin
Dermatology and Therapy (2023) Vol. 13, Iss. 2, pp. 417-435
Open Access | Times Cited: 21
Targeting IL-17 in autoimmunity and inflammation
Byung Seok Kim, Young‐Jun Park, Yeonseok Chung
Archives of Pharmacal Research (2016) Vol. 39, Iss. 11, pp. 1537-1547
Closed Access | Times Cited: 60
Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis
María C. Ovejero‐Benito, Ester Muñoz‐Aceituno, Alejandra Reolid, et al.
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 2, pp. 209-222
Closed Access | Times Cited: 52
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
Gerasimos Evangelatos, Vasiliki Koulouri, Alexios Iliopoulos, et al.
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 41
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
Benjamin Lockshin, Angel M. Cronin, Ryan W. Harrison, et al.
Dermatologic Therapy (2021) Vol. 34, Iss. 2
Open Access | Times Cited: 35
A non-clinical comparative study of IL-23 antibodies in psoriasis
Li Zhou, Yibing Wang, Qi Wan, et al.
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 33
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
Joshua Burshtein, Milaan Shah, Danny Zakria, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 2, pp. 323-339
Open Access | Times Cited: 5
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents
Andrea Chiricozzi, Marco Romanelli, Rosita Saraceno, et al.
Expert Opinion on Drug Safety (2016) Vol. 15, Iss. 12, pp. 1653-1659
Closed Access | Times Cited: 47
T Helper 17 Cells in Primary Sjögren’s Syndrome
Kiyoshi Matsui, Hajime Sano
Journal of Clinical Medicine (2017) Vol. 6, Iss. 7, pp. 65-65
Open Access | Times Cited: 40
Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report
Matthew K. Smith, Jay Pai, Remo Panaccione, et al.
BMC Gastroenterology (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 39
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
L. Puig, А. Л. Бакулев, М. М. Кохан, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 4, pp. 1319-1332
Open Access | Times Cited: 32

Scroll to top